(Q48396205)

11 February 2018

title

La lunga attesa: towards a molecular approach to neuroimaging and therapeutics in Alzheimer's disease. (English)

1 reference

11 February 2018

0 references

V L Villemagne

1

1 reference

11 February 2018

S Ng

2

1 reference

11 February 2018

R Cappai

3

1 reference

11 February 2018

K J Barnham

4

1 reference

11 February 2018

M T Fodero-Tavoletti

5

1 reference

11 February 2018

C C Rowe

6

1 reference

11 February 2018

C L Masters

7

1 reference

11 February 2018

publication date

19 October 2006

1 reference

11 February 2018

The Neuroradiology Journal

published in

1 reference

11 February 2018

volume

19

1 reference

11 February 2018

issue

4

1 reference

11 February 2018

page(s)

453-474

1 reference

11 February 2018

Alzheimer's disease and Down's syndrome: roles of APP, trophic factors and ACh.

cites work

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Alzheimer's disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Neuropathologic diagnostic outcomes from a cohort of outpatients with suspected dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Mild cognitive impairment: clinical characterization and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Tau neurofibrillary pathology and microtubule stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Neuropathology of Alzheimer's disease and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Competition for microtubule-binding with dual expression of tau missense and splice isoforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

The phosphorylation of tau: a critical stage in neurodevelopment and neurodegenerative processes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Amyloid plaque core protein in Alzheimer disease and Down syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Targeting of cell-surface beta-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Production of the Alzheimer amyloid beta protein by normal proteolytic processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

The alpha-helical to beta-strand transition in the amino-terminal fragment of the amyloid beta-peptide modulates amyloid formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

A high resolution ultrastructural comparison of isolated and in situ murine AA amyloid fibrils

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Alzheimer's disease is a synaptic failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

The genetics and molecular pathology of Alzheimer's disease: roles of amyloid and the presenilins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Alzheimer's disease: genes, proteins, and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Amyloid fibril protein nomenclature -- 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Immunoglobulin light chains, glycosaminoglycans, and amyloid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Mapping biochemistry to metabolism: FDG-PET and amyloid burden in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

The molecular pathology of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Alzheimer's disease: the amyloid cascade hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Alzheimer's and prion diseases: distinct pathologies, common proteolytic denominators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

The search for an amyloid solution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Amyloid, the presenilins and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Alzheimer's disease-do tauists and baptists finally shake hands?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Translating cell biology into therapeutic advances in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Release of excess amyloid beta protein from a mutant amyloid beta protein precursor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Two novel presenilin-1 mutations (Y256S and Q222H) are associated with early-onset Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Candidate gene for the chromosome 1 familial Alzheimer's disease locus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Metabolism of the "Swedish" amyloid precursor protein variant in neuro2a (N2a) cells. Evidence that cleavage at the "beta-secretase" site occurs in the golgi apparatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Apolipoprotein E polymorphism and Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Apolipoprotein E, Dementia, and Cortical Deposition of β-Amyloid Protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Quantitative analysis of senile plaques in Alzheimer disease: observation of log-normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21 (Down syndrome).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Increased Abeta42(43) from cell lines expressing presenilin 1 mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Detection of a novel intraneuronal pool of insoluble amyloid beta protein that accumulates with time in culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

The metallobiology of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Amyloid beta-peptide is produced by cultured cells during normal metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Neuroprotective approaches in experimental models of beta-amyloid neurotoxicity: relevance to Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Mechanisms of beta-amyloid neurotoxicity: perspectives of pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

21 January 2018

Metals and neuroscience.

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Redox-active metals, oxidative stress, and Alzheimer's disease pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Neurodegenerative diseases and oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Abeta amyloidosis induces the initial stage of tau accumulation in APP(Sw) mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Amyloid beta peptide induces tau phosphorylation and loss of cholinergic neurons in rat primary septal cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Alzheimer's disease pathogenesis and therapeutic interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Molecular basis of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Neuroprotection and neurodegenerative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Assembly of A beta amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Alzheimer's disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Evidence that the beta-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of abeta by zinc

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Prospects for pharmacological intervention in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Memantine: update on the current evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Treating the full spectrum of dementia with memantine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Memantine in moderate-to-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Antioxidants as treatment for neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: involvement of the glutathione system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Multiple antioxidants in the prevention and treatment of Alzheimer disease: analysis of biologic rationale

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Experimental excitotoxicity provokes oxidative damage in mice brain and attenuation by extract of Asparagus racemosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Phenolic antioxidants attenuate hippocampal neuronal cell damage against kainic acid induced excitotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Functional aspects of creatine kinase in brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Does mitochondrial respiratory chain dysfunction have a role in common neurodegenerative disorders?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Delay in manifestations of aging by grafting NGF cultured chromaffin cells in adulthood

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

The female sex hormone oestrogen as a neuroprotectant

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Challenges of targeting A beta fibrillogenesis and other protein folding disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Emerging beta-amyloid therapies for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Secretases as targets for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Non-cholinergic strategies for treating and preventing Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Potential novel targets for Alzheimer pharmacotherapy: I. Secretases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Beta-amyloid therapies in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Review of the next generation of Alzheimer's disease therapeutics: challenges for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Acetylcholinesterase inhibitors increase ADAM10 activity by promoting its trafficking in neuroblastoma cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

M1 receptors play a central role in modulating AD-like pathology in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

The presenilins in Alzheimer's disease--proteolysis holds the key.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Differential effects of inhibitors on the gamma-secretase complex. Mechanistic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

The gamma-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester reduces A beta levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces Abeta 42 generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Therapeutic strategies for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Vaccines for Alzheimer's disease: how close are we?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Lessons from the AN 1792 Alzheimer vaccine: lest we forget.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Anti-Abeta: The good, the bad, and the unforeseen

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Alzheimer vaccine: amyloid-beta on trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Alzheimer's vaccine: a cure as dangerous as the disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Inflammation and Alzheimer's disease pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Statins and the risk of dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Alterations of Alzheimer's disease in the cholesterol-fed rabbit, including vascular inflammation. Preliminary observations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Aqueous dissolution of Alzheimer's disease Abeta amyloid deposits by biometal depletion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Rapid induction of Alzheimer A beta amyloid formation by zinc.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Copper, iron and zinc in Alzheimer's disease senile plaques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Metal complexing agents as therapies for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Detection in life of confirmed Alzheimer's disease using a simple measurement of medial temporal lobe atrophy by computed tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Volumes of the entorhinal and perirhinal cortices in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Mapping hippocampal and ventricular change in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

A comparison of medial and lateral temporal lobe atrophy in dementia with Lewy bodies and Alzheimer's disease: magnetic resonance imaging volumetric study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Early diagnosis of Alzheimer's disease: contribution of structural neuroimaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

MRI measures of entorhinal cortex vs hippocampus in preclinical AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Neuroimaging and early diagnosis of Alzheimer disease: a look to the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Hydrogen magnetic resonance spectroscopy in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Selective reduction of N-acetylaspartate in medial temporal and parietal lobes in AD

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

MRI of entorhinal cortex in mild Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Application of positron emission tomography for evaluation of metabolism and blood flow in human brain: normal development, aging, dementia, and stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Imaginem oblivionis: the prospects of neuroimaging for early detection of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Transient and sustained activity in a distributed neural system for human working memory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Alzheimer's disease histologically proven studied by MRI and MRS: two cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

In vivo proton magnetic resonance spectroscopy of Alzheimer's disease in the parietal and temporal lobes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

N-acetyl-L-aspartate and other amino acid metabolites in Alzheimer's disease brain: a preliminary proton nuclear magnetic resonance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Brain proton magnetic resonance spectroscopy (1H-MRS) in Alzheimer's disease: changes after treatment with xanomeline, an M1 selective cholinergic agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Brain MR spectroscopy at 1.0 tesla.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Mild cognitive impairment and Alzheimer disease: regional diffusivity of water

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Loss of connectivity in Alzheimer's disease: an evaluation of white matter tract integrity with colour coded MR diffusion tensor imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Positron emission tomography and single-photon emission computed tomography brain imaging in the evaluation of dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Accuracy of early diagnosis and its impact on the management and course of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

The course of psychopathologic features in mild to moderate Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Positron emission tomography diagnosis of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Added Clinical Benefit of Incorporating 2-Deoxy-2-[F]Fluoro-D-Glucose with Positron Emission Tomography into the Clinical Evaluation of Patients with Cognitive Impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

A clinical role for 99mTc-HMPAO SPECT in the investigation of dementia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Alzheimer's disease and frontotemporal dementia are differentiated by discriminant analysis applied to (99m)Tc HmPAO SPECT data

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Frontotemporal dementia can be distinguished from Alzheimer's disease and subcortical white matter dementia by an anterior-to-posterior rCBF-SPET ratio.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Regional cerebral blood flow difference between dementia with Lewy bodies and AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Preclinical prediction of Alzheimer's disease using SPECT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Presenilin-1-associated abnormalities in regional cerebral perfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Imaging brain cholinergic activity with positron emission tomography: its role in the evaluation of cholinergic treatments in Alzheimer's dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

[125/123I]IPH: a radioiodinated analog of epibatidine for in vivo studies of nicotinic acetylcholine receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Synthesis of an I-123 analog of A-85380 and preliminary SPECT imaging of nicotinic receptors in baboon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

In vivo detection of neurotransmitter changes in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Clinical studies in Alzheimer patients with positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Imaging of nicotinic and muscarinic receptors in Alzheimer's disease: effect of tacrine treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Histamine H(1) receptors in patients with Alzheimer's disease assessed by positron emission tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Neuroimaging as a diagnostic tool in dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

PET shows that striatal dopamine D1 and D2 receptors are differentially affected in AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Serotonin 1A receptors in the living brain of Alzheimer's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Imaging of the 5-HT2A system: age-, gender-, and Alzheimer's disease-related findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Opiate receptor avidity and cerebral blood flow in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

123Iodo-MK-801: a spect agent for imaging the pattern and extent of glutamate (NMDA) receptor activation in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Muscarinic receptors in basal ganglia in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

In vivo amyloid imaging in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Detection of amyloid plaques in mouse models of Alzheimer's disease by magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Detection of neuritic plaques in Alzheimer's disease by magnetic resonance microscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

19F and 1H MRI detection of amyloid beta plaques in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Fluoro-substituted and 13C-labeled styrylbenzene derivatives for detecting brain amyloid plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

IMPY: an improved thioflavin-T derivative for in vivo labeling of beta-amyloid plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

11C-labeled stilbene derivatives as Abeta-aggregate-specific PET imaging agents for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Detection of amyloid plaques by radioligands for Abeta40 and Abeta42: potential imaging agents in Alzheimer's patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Visualization of fibrillar amyloid deposits in living, transgenic Caenorhabditis elegans animals using the sensitive amyloid dye, X-34.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

IBOX(2-(4'-dimethylaminophenyl)-6-iodobenzoxazole): a ligand for imaging amyloid plaques in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Isomerization of (Z,Z) to (E,E)1-bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene in strong base: probes for amyloid plaques in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Novel stilbenes as probes for amyloid plaques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

F-18 Polyethyleneglycol stilbenes as PET imaging agents targeting Abeta aggregates in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-(1-[6-[(2-[(18)F]fluoroethyl)(methyl)amino]-2-naphthyl]ethylidene)malononitrile

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

In vivo brain imaging of tangle burden in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Amyloid binding ligands as Alzheimer's disease therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Noninvasive imaging of peripherally injected Alzheimer's disease type synthetic A beta amyloid in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Prospects for noninvasive imaging of brain amyloid beta in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Abeta(1-40) peptide radiopharmaceuticals for brain amyloid imaging: (111)In chelation, conjugation to poly(ethylene glycol)-biotin linkers, and autoradiography with Alzheimer's disease brain sections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Vector-mediated delivery of 125I-labeled beta-amyloid peptide A beta 1-40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the A beta 1-40/vector complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Labeling of cerebral amyloid in vivo with a monoclonal antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Noninvasive in vivo MRI detection of neuritic plaques associated with iron in APP[V717I] transgenic mice, a model for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Histological co-localization of iron in Abeta plaques of PS/APP transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Imaging technology for neurodegenerative diseases: progress toward detection of specific pathologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Delineation of positron emission tomography imaging agent binding sites on beta-amyloid peptide fibrils.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Evidence for the presence of three distinct binding sites for the thioflavin T class of Alzheimer's disease PET imaging agents on beta-amyloid peptide fibrils.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Mild cognitive impairment represents early-stage Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Phases of A beta-deposition in the human brain and its relevance for the development of AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Amyloid imaging: from benchtop to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Current progress in beta-amyloid immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Medial Temporal Lobe Width on CT Scanning in Alzheimer’s Disease: Comparison with Vascular Dementia, Depression and Dementia with Lewy Bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

The Aβ Peptide of Alzheimer's Disease Directly Produces Hydrogen Peroxide through Metal Ion Reduction†

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F197140090601900406

10.1177/197140090601900406

21 January 2018

Identifiers

DOI

1 reference

11 February 2018

PubMed ID

24351248

1 reference

11 February 2018